| Dr Zackery Logan Gene Fowler, DO | |
|
901 N Porter Ave, Norman, OK 73071-6404 | |
| (405) 307-1000 | |
| Not Available |
| Full Name | Dr Zackery Logan Gene Fowler |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 3 Years |
| Location | 901 N Porter Ave, Norman, Oklahoma |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194395863 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 0475R (Oklahoma) | Secondary |
| 207P00000X | Emergency Medicine | 7669 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Purcell Municipal Hospital | Purcell, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emergency Physicians Of Mid-america Pc | 2062638661 | 80 |
News Archive
Scientists on the cutting edge of biomedical research know that research is a process - a combination of successes and failures that inform the next step forward. However, for some researchers at The Ohio State University progress means taking a step back. Supported by the Ohio State University Center for Clinical and Translational Science (CCTS), these scientists are using failed and forgotten research to uncover future treatments for major health conditions as diverse as oral cancer and stroke.
An essential aspect of oral surgery is controlling the patient's pain following a procedure. The goal is to relieve pain and promote a rapid recovery, without opioid side effects. An initial study shows that Dyloject, a new intravenous form of the drug diclofenac, has promise for achieving these goals.
When choosing a doctor based on increasingly popular "doctor report cards," patients should be aware that the areas in which physicians are graded are not always clear-cut, according to researchers from the Johns Hopkins Bloomberg School of Public Health and School of Medicine.
Genzyme Corporation announced today that it has received a June 17, 2010 PDUFA date from the FDA for its Biologics License Application for Lumizyme™ (alglucosidase alfa) seeking approval for the therapy produced at the 4000 L scale.
Microscopic amounts of blood in urine have been considered a risk factor for urinary tract malignant tumors. However, only a small proportion of patients referred for investigation are subsequently found to have cancer. A new Kaiser Permanente Southern California study published in the February Mayo Clinic Proceedings reports on the development and testing of a Hematuria Risk Index to predict cancer risk.
› Verified 6 days ago
| Entity Name | Emergency Physicians Of Mid-america Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063825297 PECOS PAC ID: 2062638661 Enrollment ID: O20140716001692 |
News Archive
Scientists on the cutting edge of biomedical research know that research is a process - a combination of successes and failures that inform the next step forward. However, for some researchers at The Ohio State University progress means taking a step back. Supported by the Ohio State University Center for Clinical and Translational Science (CCTS), these scientists are using failed and forgotten research to uncover future treatments for major health conditions as diverse as oral cancer and stroke.
An essential aspect of oral surgery is controlling the patient's pain following a procedure. The goal is to relieve pain and promote a rapid recovery, without opioid side effects. An initial study shows that Dyloject, a new intravenous form of the drug diclofenac, has promise for achieving these goals.
When choosing a doctor based on increasingly popular "doctor report cards," patients should be aware that the areas in which physicians are graded are not always clear-cut, according to researchers from the Johns Hopkins Bloomberg School of Public Health and School of Medicine.
Genzyme Corporation announced today that it has received a June 17, 2010 PDUFA date from the FDA for its Biologics License Application for Lumizyme™ (alglucosidase alfa) seeking approval for the therapy produced at the 4000 L scale.
Microscopic amounts of blood in urine have been considered a risk factor for urinary tract malignant tumors. However, only a small proportion of patients referred for investigation are subsequently found to have cancer. A new Kaiser Permanente Southern California study published in the February Mayo Clinic Proceedings reports on the development and testing of a Hematuria Risk Index to predict cancer risk.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Zackery Logan Gene Fowler, DO 3619 Chatham Ct, Norman, OK 73072-4228 Ph: () - | Dr Zackery Logan Gene Fowler, DO 901 N Porter Ave, Norman, OK 73071-6404 Ph: (405) 307-1000 |
News Archive
Scientists on the cutting edge of biomedical research know that research is a process - a combination of successes and failures that inform the next step forward. However, for some researchers at The Ohio State University progress means taking a step back. Supported by the Ohio State University Center for Clinical and Translational Science (CCTS), these scientists are using failed and forgotten research to uncover future treatments for major health conditions as diverse as oral cancer and stroke.
An essential aspect of oral surgery is controlling the patient's pain following a procedure. The goal is to relieve pain and promote a rapid recovery, without opioid side effects. An initial study shows that Dyloject, a new intravenous form of the drug diclofenac, has promise for achieving these goals.
When choosing a doctor based on increasingly popular "doctor report cards," patients should be aware that the areas in which physicians are graded are not always clear-cut, according to researchers from the Johns Hopkins Bloomberg School of Public Health and School of Medicine.
Genzyme Corporation announced today that it has received a June 17, 2010 PDUFA date from the FDA for its Biologics License Application for Lumizyme™ (alglucosidase alfa) seeking approval for the therapy produced at the 4000 L scale.
Microscopic amounts of blood in urine have been considered a risk factor for urinary tract malignant tumors. However, only a small proportion of patients referred for investigation are subsequently found to have cancer. A new Kaiser Permanente Southern California study published in the February Mayo Clinic Proceedings reports on the development and testing of a Hematuria Risk Index to predict cancer risk.
› Verified 6 days ago
Jonathan Wright I, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 901 N Porter Ave, Attention Physician Residency, Norman, OK 73071 Phone: 405-307-5340 | |
Dr. Olivia Danielle Reed, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 901 N Porter Ave, Norman, OK 73071 Phone: 405-307-1000 | |
Dr. Spencer Robert Baird, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 901 N Porter Ave, Norman, OK 73071 Phone: 706-296-1258 | |
Dr. Dylan Rommel, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 901 N Porter Ave, Norman, OK 73071 Phone: 405-307-1000 | |
Arthur Maduabia, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 901 N Porter Ave, Norman, OK 73071 Phone: 405-307-5340 | |
Crystal Helena Goree, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 901 N Porter Ave, Norman, OK 73071 Phone: 405-307-1392 | |
Robert Francisco Sanchez, DO Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 901 N Porter Ave, Norman, OK 73071 Phone: 405-307-1392 |